BDTX - Company ID 0001701541
The table below shows Black Diamond Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $70.00M | $0.00 | $0.00 |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $7.00M | $7.44M | $9.32M | $10.51M | $12.91M | $12.56M |
Black Diamond Therapeutics, Inc. reported annual revenue of $70.00M for fiscal year 2025. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $4.26M |
| $3.54M |
| $4.10M |
| $4.96M |
| $5.22M |
| $9.57M |
| Operating income | -$11.26M | -$10.98M | -$13.42M | $54.53M | -$18.13M | -$22.13M |
| Income tax | - | - | - | $226.00K | - | - |
| Net income | -$9.04M | -$8.50M | -$10.56M | $56.54M | -$15.56M | -$19.91M |
| EPS (diluted) | -$0.16 | -$0.15 | -$0.19 | $0.98 | -$0.28 | -$0.36 |